PharmacoEconomics

A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing?
pp. 1-9(9)
Author: Drummond M.F.

The Role of Pharmacoeconomic Evaluations in Disease Management
pp. 11-17(7)
Authors: Chang K.; Nash D.

The Impact of Managed Care on Clinical Research
pp. 19-25(7)
Authors: McKee M.; Mossialos E.

Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
pp. 27-48(22)
Authors: Brown A.D.; Garber A.M.

The Economics of TRACE: A Cost-Effectiveness Analysis of Trandolapril in Postinfarction Patients with Left Ventricular Dysfunction
pp. 49-58(10)
Authors: LePen C.; Lilliu H.; Keller T.; Fiessinger S.

The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients: A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin
pp. 59-70(12)
Authors: McLain R.W.; Koren M.J.; Bakker-Arkema R.G.; Smith D.G.; Black D.M.; Hunninghake D.B.; Davidson M.H.; McKenney J.M.; Weiss S.R.; Schrott H.G.; Henley R.W.J.; Tresh P.

A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information
pp. 71-77(7)
Authors: Woodward R.S.; Amir L.; Schnitzler M.A.; Brennan D.C.

The Use of Decision-Analytical Modelling in Economic Evaluation of Patch Testing in Allergic Contact Dermatitis
pp. 79-95(17)
Authors: Rajagopalan R.; Anderson R.T.; Sarma S.; Retchin C.; Jones J.

Risperidone: A Pharmacoeconomic Review of its Use in Schizophrenia
pp. 97-133(37)
Authors: Foster R.H.; Goa K.L.

‘The Pros and Cons of a Single Euro-Price for Drugs’ and ‘The Economics of Parallel Trade’
pp. 135-137(3)
Author: Rovira J.

‘The Pros and Cons of a Single Euro-Price for Drugs’ and ‘The Economics of Parallel Trade’
pp. 135-137(3)
Authors: Danzon P.; Towse A.